½ÃÀ庸°í¼­
»óǰÄÚµå
1691686

¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå(2024-2030³â)

Antimicrobial Resistance Diagnostics Market, Global, 2024-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Frost & Sullivan | ÆäÀÌÁö Á¤º¸: ¿µ¹® 49 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀüÀå À¯Àüü ¿°±â¼­¿­ ºÐ¼®°ú ¸ÖƼÇ÷º½º °Ë»ç·ÎÀÇ ÀüȯÀº ¼Óµµ, Á¤È®µµ, ³ôÀº 󸮷® Áõ°¡¸¦ ÅëÇÑ Çõ½ÅÀû ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

Ç×±ÕÁ¦°¡ µèÁö ¾Ê´Â ¹ÚÅ׸®¾Æ, ¹ÙÀÌ·¯½º, °õÆÎÀ̸¦ Ư¡À¸·Î ÇÏ´Â AMRÀº ¼¼°è °øÁߺ¸°ÇÀÇ 10´ë À§Çù Áß ÇϳªÀÔ´Ï´Ù. º´¿øÃ¼°¡ ¾àÁ¦ ³»¼ºÀ» ȹµæÇÏ¸é ¾à¹°ÀÌ µèÁö ¾Ê¾Æ ÆÐÇ÷ÁõÀ» À¯¹ßÇÏ´Â °¨¿°À» ÀÏÀ¸ÄÑ ÁßÁõÈ­, Àå¾Ö, »ç¸ÁÀÇ À§ÇèÀ» Å©°Ô Áõ°¡½Ãŵ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÀÎü °Ç°­ °ü·Ã Ç×±ÕÁ¦ ³»¼º(AMR) Áø´Ü ½ÃÀåÀ» Á¶»çÇß½À´Ï´Ù. ¸ÅÃâ ¹× ¸ÅÃâ ¿¹ÃøÀ» À§ÇÑ Ç¥ÇöÇü °Ë»ç ¹× ºÐÀÚ °Ë»ç, °æÀï ȯ°æÀ» ºÐ¼®Çϰí, ±â±â, ¼Ò¸ðǰ, ÀÎÆ÷¸Åƽ½º¸¦ Æ÷ÇÔÇÑ IVD Ç÷§ÆûÀ» Á¦°øÇÏ´Â º¥´õ(Á¦Á¶¾÷ü)¸¦ ½Äº°ÇÕ´Ï´Ù. º´¿ø, Áø·á¼Ò, Áø´Ü ½ÇÇè½Ç, ±âŸ°¡ ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚÀÔ´Ï´Ù. ¶ÇÇÑ ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ Áö¿ªº° ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼­´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ°í ¾ïÁ¦ÇÏ´Â ¿äÀÎÀ» ºÐ¼®Çϰí ÁÖ¿ä ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ¿© ½ÃÀå Âü¿©ÀÚ¿Í ÀÌÇØ°ü°èÀÚ°¡ µ¿ÇâÀ» ÆÄ¾ÇÇÏ°í °æÁ¦Àû ÀáÀç·ÂÀ» ±Ø´ëÈ­ÇÏ°í °¡Ä¡¸¦ Áö¼ÓÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ±âÁØ ¿¬µµ´Â 2024³â, ¿¹Ãø ±â°£Àº 2025-2030³âÀÔ´Ï´Ù.

¸ñÂ÷

¼ºÀå ±âȸ : Á¶»ç ¹üÀ§

  • ºÐ¼® ¹üÀ§
  • ¼¼ºÐÈ­

¼ºÀå ȯ°æ : AMR Áø´Ü ½ÃÀåÀÇ º¯Çõ

  • ¼ºÀåÀÌ Á¡Á¡ ´õ ¾î·Á¿öÁö´Â ÀÌÀ¯
  • Àü·«Àû Çʼö ¿ä°Ç
  • AMR Áø´Ü ¾÷°è¿¡ ´ëÇÑ 3°³ Àü·«Àû Çʼö ¿ä¼ÒÀÇ ¿µÇâ

AMR Áø´Ü ½ÃÀå »ýŰè

  • °æÀï ȯ°æ
  • ÁÖ¿ä °æÀï»ç

AMR Áø´Ü ½ÃÀå ¼ºÀå¿äÀÎ

  • ¼ºÀå ÁöÇ¥
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ¿¹Ãø °ËÅä
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç°º° ¸ÅÃâ ¿¹Ãø
  • Áö¿ªº° ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø ºÐ¼®
  • °¡°Ý µ¿Çâ°ú ¿¹Ãø ºÐ¼®
  • ¸ÅÃ⠺йè
  • °æÀï ¸ÅÆ®¸¯½º - Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
  • ¸ÅÃâ ºÐ¹è ºÐ¼®

Ç¥ÇöÇü Å×½ºÆ®¸¦ À§ÇÑ ¼ºÀå ÃËÁø¿äÀÎ

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • Áö¿ªº° ¸ÅÃâ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®

ºÐÀÚ °Ë»ç¸¦ À§ÇÑ ¼ºÀå ÃËÁø¿äÀÎ

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • Áö¿ªº° ¸ÅÃâ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®

¼ºÀå ±âȸ

  • ¼ºÀå ±âȸ 1 : ºÐÀÚ °Ë»ç¸¦ ÁÖµµÇÏ´Â WGS
  • ¼ºÀå ±âȸ 2 : ¸ÖƼÇ÷º½º POCT
  • ¼ºÀå ±âȸ 3 : ¹Î°£ ¹× °ø°ø ÆÄÆ®³Ê½ÊÀ» ÅëÇÑ Ç×±Õ ½ºÆ©¾îµå½Ê

ºÎ·Ï°ú ´ÙÀ½ ´Ü°è

LSH 25.04.08

The Shift to Whole-genome Sequencing and Multiplex Point-of-care Testing is Driving Transformational Growth Due to Improved Speed, Accuracy, and High Throughput

This Frost & Sullivan report examines the antimicrobial resistance (AMR) diagnostics market in human health. AMR, characterized by bacteria, viruses, and fungi that no longer respond to antimicrobial medications, is one of the top ten global public health threats. When pathogens develop drug resistance, medications become ineffective, leading to infections that may trigger sepsis and significantly increase the risk of severe illness, disability, and death. Covering in vitro diagnostics (IVD) methods, this report includes phenotypic and molecular tests for revenue and forecast estimations. It analyzes the competitive environment, identifying vendors (manufacturers) offering IVD platforms, including instruments, consumables, and informatics. Hospitals, clinics, diagnostic labs, and others encompass key end-user verticals.

The analysis offers a region-wise forecast for North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. The study analyzes the factors driving and restraining the growth of this market and identifies key growth opportunities to help market players and stakeholders build on trends, maximize economic potential, and sustain value. The base year is 2024, and the forecast period is from 2025 to 2030.

Table of Contents

Growth Opportunities: Research Scope

  • Scope of Analysis
  • Segmentation

Growth Environment: Transformation in the AMR Diagnostics Market

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the AMR Diagnostics Industry

Ecosystem in the AMR Diagnostics Market

  • Competitive Environment
  • Key Competitors

Growth Generators in the AMR Diagnostics Market

  • Growth Metrics
  • Growth Drivers
  • Growth Restraints
  • Forecast Considerations
  • Revenue Forecast
  • Revenue Forecast by Product
  • Revenue Forecast by Region
  • Revenue Forecast Analysis
  • Pricing Trends and Forecast Analysis
  • Revenue Share
  • Competitor Matrix-Product Portfolio Analysis
  • Revenue Share Analysis

Growth Generators for Phenotypic Tests

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Region
  • Forecast Analysis

Growth Generators for Molecular Tests

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Region
  • Forecast Analysis

Growth Opportunity Universe

  • Growth Opportunity 1: WGS Driving Molecular Tests
  • Growth Opportunity 2: Multiplex POCT
  • Growth Opportunity 3: Antimicrobial Stewardship Through Private-Public Partnerships

Appendix & Next Steps

  • Benefits and Impacts of Growth Opportunities
  • Next Steps
  • List of Exhibits
  • Legal Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦